1. The rate of progression was 57% lower in the group receiving anal HSIL treatment as compared to the group...
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal...
1. The circulating tumour DNA-guided approach was non-inferior to the standard clinicopathological approach in terms of 2-year recurrence-free survival. 2....
1. Long-term plant-based diet was associated with more variance in microbial structure and future cardiometabolic biomarkers, suggesting a possible protective...
1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies. 2....
1. Evidence is mixed regarding the relationship between childhood obesity and food insecurity in longitudinal studies, with study heterogeneity limiting broader...
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse...
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE...
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4...
1. In a retrospective cohort study of approximately 73,000 children with non-perforated appendicitis, 14% were managed non-operatively with antibiotics, of which 20% experienced subsequent...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.